Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia

NCT07187375 is registered in ClinicalTrials.gov with Neurocrine Switzerland GmbH as lead sponsor.

NCT NCT07187375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia
Lead sponsor
Neurocrine Switzerland GmbH
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 30, 2025
Completion date
October 4, 2029
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia